TARS: Tarsus Pharmaceuticals, Inc. Quarterly EPS earnings growth

The reliability of Tarsus Pharmaceuticals (TARS) is based on the management of regulatory risks and a focused portfolio of ophthalmological products. The quarterly EPS growth rate on GURU.Markets reflects the precise execution of the strategy, where the value is maintained at -4796.30. High patent barriers protect developments, while the rapid market penetration of the blepharitis drug confirms the colossal demand for innovative therapy.

Tarsus Pharmaceuticals Inc (TARS) - Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 11/15/2026

Summary analytical data breakdowns for tarsusrx.com (TARS)

- share price and expert price forecast:

Stock Price Tarsus Pharmaceuticals, Inc.|TARS - Forecast Levels Chart

- market capitalization information:

Market Capitalization Tarsus Pharma|TARS - Total Enterprise Value

- balance sheet net asset value indicators:

Book Value per Share Tarsus Pharmaceuticals|TARS - Company Net Assets|Market Cap to Net Assets Ratio tarsusrx.com|TARS - Aggregate Business Assets

- company liabilities and liquidity data:

Total Debt to Capital Tarsus Pharmaceuticals|TARS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Tarsus Corp|TARS - Company Cumulative Debt|Debt to Book Capitalization Ratio Tarsus Pharmaceuticals Inc|TARS - Company Long-Term Indebtedness|Company Short-Term Debt Tarsus Pharmaceuticals|Quick Liquidity Indicator tarsusrx.com

- earnings and valuation multiples indicators:

TARS - Profit After Payment of Taxes|Projected Future Earnings Tarsus Pharmaceuticals|TARS - P/E Multiple|Future Price to Earnings Tarsus Pharmaceuticals|TARS - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tarsus Pharmaceuticals Inc|TARS - Operating income before deduction of amortization|Net earnings per share for the last 12 months Tarsus Pharmaceuticals|TARS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months tarsusrx.com|TARS - Expected net earnings per share growth this year|Expected earnings per share growth for next year Tarsus Pharmaceuticals

- revenue and sales proceeds data:

TARS - Company Sales Revenue|Company Projected Revenue Tarsus Pharmaceuticals, Inc.|TARS - Price-to-Sales Ratio|Forward P/S Multiple Tarsus Pharmaceuticals, Inc.|TARS - Revenue Dynamics YoY (Last Twelve Months)

Comprehensive company analysis:Tarsus Pharmaceuticals

Flagship merchandise of Tarsus Pharmaceuticals

This metric is calculated as the percentage deviation of current earnings per share from the value of the same period last year. This metric measures the efficiency of generating net income available to shareholders after all operating expenses. For Tarsus Pharmaceuticals (TARS), this rate reflects the commercial success of sales for its ophthalmologic drug against blepharitis. Analyzing the quarterly EPS change allows for the identification of a systemic slowdown in profitability. Stable growth on this chart confirms the quality of capital management.

Key competitors